ITOS vs. JSPR, AVXL, MGTX, LXEO, IVVD, HUMA, TSHA, MGX, GLUE, and ADVM
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Jasper Therapeutics (JSPR), Anavex Life Sciences (AVXL), MeiraGTx (MGTX), Lexeo Therapeutics (LXEO), Invivyd (IVVD), Humacyte (HUMA), Taysha Gene Therapies (TSHA), Metagenomi (MGX), Monte Rosa Therapeutics (GLUE), and Adverum Biotechnologies (ADVM). These companies are all part of the "biological products, except diagnostic" industry.
iTeos Therapeutics (NASDAQ:ITOS) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.
iTeos Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.
In the previous week, iTeos Therapeutics and iTeos Therapeutics both had 3 articles in the media. iTeos Therapeutics' average media sentiment score of 0.42 beat Jasper Therapeutics' score of 0.17 indicating that iTeos Therapeutics is being referred to more favorably in the media.
iTeos Therapeutics currently has a consensus price target of $30.33, indicating a potential upside of 130.32%. Jasper Therapeutics has a consensus price target of $62.50, indicating a potential upside of 116.86%. Given iTeos Therapeutics' higher possible upside, analysts plainly believe iTeos Therapeutics is more favorable than Jasper Therapeutics.
Jasper Therapeutics has lower revenue, but higher earnings than iTeos Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
iTeos Therapeutics received 7 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 81.48% of users gave Jasper Therapeutics an outperform vote while only 72.50% of users gave iTeos Therapeutics an outperform vote.
iTeos Therapeutics' return on equity of -18.40% beat Jasper Therapeutics' return on equity.
97.2% of iTeos Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 10.2% of iTeos Therapeutics shares are held by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
iTeos Therapeutics beats Jasper Therapeutics on 10 of the 14 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
iTeos Therapeutics Competitors List
Related Companies and Tools